10x Genomics, Inc. (TXG) |
| 61.65 1.67 (2.78%) 09-02 16:00 |
| Open: | 60.24 |
| High: | 63.49 |
| Low: | 59.5 |
| Volume: | 1,604,525 |
| Market Cap: | 7,827(M) |
| PE Ratio: | -104.49 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Healthcare Information Services |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 78.19 |
| Resistance 1: | 66.94 |
| Pivot price: | 61.49 |
| Support 1: | 53.00 |
| Support 2: | 44.39 |
| 52w High: | 66.94 |
| 52w Low: | 11.16 |
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
| EPS | -0.590 |
| Book Value | 6.310 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.598 |
| Profit Margin (%) | -12.18 |
| Operating Margin (%) | -15.20 |
| Return on Assets (ttm) | -5.1 |
| Return on Equity (ttm) | -9.4 |
Tue, 01 Sep 2026
A Look at 10x Genomics Inc (TXG) After 4.0% Decline -- GF Value $18.36 vs Price $60.00 - gurufocus.com
Mon, 31 Aug 2026
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences - Yahoo Finance
Fri, 28 Aug 2026
10x Genomics wins jury award in Qiagen patent row (TXG:NASDAQ) - Seeking Alpha
Fri, 28 Aug 2026
A jury found Qiagen subsidiary Parse willfully infringed three patents; 10x won damages - Stock Titan
Wed, 26 Aug 2026
10x Genomics Inc (TXG) Director Shehnaaz Suliman Sells 2,207 Sha - gurufocus.com
Wed, 26 Aug 2026
10x Genomics director sells 2,207 shares | TXG Insider Trading - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |